$5.23
2.34% today
Nasdaq, Feb 28, 04:43 pm CET
ISIN
US4525253062
Symbol
ICCC

ImmuCell Corporation Stock price

$5.35
+0.11 2.10% 1M
+1.21 29.23% 6M
+0.20 3.88% YTD
+0.21 4.09% 1Y
-2.82 34.52% 3Y
+0.48 9.86% 5Y
-1.30 19.55% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.13 2.37%
ISIN
US4525253062
Symbol
ICCC
Sector

Key metrics

Market capitalization $47.68m
P/E (TTM) P/E ratio negative
P/S ratio (TTM) P/S ratio 1.80
P/B ratio (TTM) P/B ratio 1.79
Revenue growth (TTM) Revenue growth 51.63%
Revenue (TTM) Revenue $26.49m
EBIT (operating result TTM) EBIT $-1.64m
Cash position $3.76m
EPS (TTM) EPS $-0.28
Short interest 0.06%
Show more

Is ImmuCell Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Financial data from ImmuCell Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
26 26
52% 52%
100%
- Direct Costs 19 19
36% 36%
70%
7.94 7.94
105% 105%
30%
- Selling and Administrative Expenses 2.98 2.98
21% 21%
11%
- Research and Development Expense 3.90 3.90
11% 11%
15%
1.06 1.06
135% 135%
4%
- Depreciation and Amortization 2.70 2.70
2% 2%
10%
EBIT (Operating Income) EBIT -1.64 -1.64
71% 71%
-6%
Net Profit -2.16 -2.16
63% 63%
-8%

In millions USD.

Don't miss a Thing! We will send you all news about ImmuCell Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ImmuCell Corporation Stock News

Neutral
Seeking Alpha
2 days ago
ImmuCell Corporation (NASDAQ:ICCC ) Q4 2024 Earnings Conference Call February 26, 2025 9:00 AM ET Company Participants Joe Diaz - Managing Partner, Lytham Partners, LLC Michael Brigham - President and Chief Executive Officer Conference Call Participants George Melas-Kyriazi - MKH Management Operator Good morning, and welcome to ImmuCell Corporation Reports its Fourth Quarter and Year Ended Dece...
Neutral
GlobeNewsWire
3 days ago
PORTLAND, Maine, Feb. 25, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter and year ended December 31, 2024.
Neutral
GlobeNewsWire
8 days ago
Conference Call Scheduled for Wednesday, February 26, 2025 at 9:00 AM ET Conference Call Scheduled for Wednesday, February 26, 2025 at 9:00 AM ET
More ImmuCell Corporation News

Company Profile

ImmuCell Corp. engages in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries. Its products include first defense for scours, California mastitis test kit and purified nisin intramammary treatment for mastitis. The company was founded in 1982 and is headquartered in Portland, ME.

Head office United States
CEO Michael Brigham
Founded 1982
Website www.immucell.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today